INTRODUCTION
Interleukin-11 (IL-11) is a stromal-cell-derived growth factor that has been shown to induce multiple responses in lymphopoietic and haematopoietic cells [1] [2] [3] . In combination with other growth factors, IL-11 stimulates the proliferation of multi-lineage progenitors [4] . IL-11 acts directly on megakaryocytes and megakaryocyte precursors [5] , and on erythroid progenitors [6] . IL-11, in combination with steel factor, erythropoietin and IL-7, can support clonal expansion of individual primitive lymphohaematopoietic progenitors and their commitment to B cell [7] , natural killer [8] or T cell [9] lineages. IL-11 belongs to a family of cytokines named the IL-6-type cytokines. Members of this family, including IL-6, IL-11, leukaemia inhibitory factor, ciliary neurotropic factor, oncostatin M, cardiotrophin-1 and a new member called novel neurotrophin-1\B cell stimulating factor-3, share the use of the signal transducer gp130 for signalling through their receptor complex [10, 11] .
IL-11 signals through the JAK (Janus kinase)\STAT (signal transducer and activator of transcription) signalling pathway. Ligand binding to the specific receptor (IL-11 receptor α chain ; IL-11Rα) [12, 13] triggers dimerization of gp130 [14] , transient activation of tyrosine kinases of the JAK family [15] [16] [17] and subsequent phosphorylation of a number of tyrosine residues within gp130. The phosphorylated receptor chain provides docking sites for the proteins STAT1 and STAT3 [18, 19] . Binding of STATs to the activated receptor leads to their tyrosine phosphorylation by JAKs. Activated STATs dissociate from the receptor, dimerize, translocate into the nucleus, bind to cisacting elements (TTCN $ GAA) and transactivate several cytokine-responsive genes.
Previous studies have shown that IL-3 and IL-6-type cytokines (such as IL-6 or IL-11) may act antagonistically along Blymphocyte development [20, 21] . The underlying mechanisms by Abbreviations used : IL-11 (etc.), interleukin-11 (etc.) ; JAK, Janus kinase ; IL-11Rα, IL-11 receptor α chain ; STAT, signal transducer and activator of transcription ; SH2, Src homology 2 ; CIS, cytokine-inducible SH2-domain-containing protein ; SOCS, suppressor of cytokine signalling ; MAP kinase, mitogen-activated protein kinase ; ERK, extracellular-signal-regulated kinase ; mAb, monoclonal antibody ; MEK, MAP kinase/ERK kinase ; JNK, c-Jun N-terminal kinase. 1 To whom correspondence should be addressed (e-mail sminviel!nantes.inserm.fr).
SOCS-3 (suppressor of cytokine signalling-3) protein.
In addition, overexpression of SOCS-3 in the pro-B cell line effectively blocked STAT3 activation induced by IL-11. These findings establish that a cytokine (IL-3) that has been shown to modulate its own signal of activation is also able to down-regulate signalling activated by a different cytokine (IL-11). This cross-talk involves activation of the JAK (Janus kinase)\STAT signalling pathway, but not mitogen-activated protein kinase pathways, and is mediated, at least in part, by SOCS-3.
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which IL-3 inhibits IL-11 activity are not yet understood. Since IL-11 acts through the JAK\STAT signalling pathway, we wanted to determine whether IL-3 could modulate cellular responses to IL-11 by interfering with activation of this pathway.
Our results establish that IL-3 suppresses the IL-11-induced tyrosine phosphorylation and nuclear translocation of STAT3 in a pro-B cell line. This inhibition of STAT3 activity occurred within 30 min and required the synthesis of a negative regulator. Production of this inhibitor is independent of the extracellularsignal-regulated protein kinase (ERK) and p38 mitogen-activated protein (MAP) kinase pathways. We found that stimulation of the pro-B cells with IL-3 induced the expression of CIS (cytokineinducible SH2-domain-containing protein) and SOCS-3 (suppressor of cytokine signalling-3), two members of the recently described family of JAK\STAT signalling pathway inhibitors [22] [23] [24] [25] [26] (SH2 is Src homology 2). We found that SOCS-3 production, but not CIS production, is correlated temporally with the inhibitory effect of IL-3. Furthermore, constitutive SOCS-3 expression is able to inhibit IL-11 signalling to STAT3. These findings demonstrate that inhibition by IL-3 of IL-11 signalling is mediated, at least in part, by SOCS-3, and suggest a critical role for SOCS-3 in negative cross-talk between haematopoietic cytokines.
MATERIALS AND METHODS

Cell culture and transfection
The mouse pro-B cells Ba\F3 [27] were engineered to express the IL-11 receptor complex. Experimental procedures have been described previously [28] . Ba\F3 cells harbouring human IL-11Rα and gp130 (referred as B13Rα) were grown in RPMI 1640 containing 2 % (v\v) foetal calf serum, 1 % (w\v) glutamine, 0.8 mg\ml G418 (Sigma Chemical Co., St. Louis, MO, U.S.A.), 5 µg\ml puromycin (Sigma Chemical Co.) and 5 ng\ml human IL-11. B13Rα cells were cultured in X-VIVO culture medium (Bio-Whitaker, Walkersville, MD, U.S.A.) lacking serum and growth factors for 3 h before stimulation experiments.
Full-length human SOCS-3 was amplified by reverse transcription-PCR using the following primers : sense, 5h-GCGGATCC-ATGGTCACCCACAGCAAG ; antisense, 5h-GCGAATTCA-AGCGGGGCATCGTACTGGT. The resulting fragment was cloned into the BamHI and EcoRI sites of the pcDNA3.1\His vector (Invitrogen Corp., San Diego, CA, U.S.A.). DNA fragments were verified by double-strand DNA sequence analysis. B13Rα cells (5i10') were transiently transfected by electroporation (900 µF, 300 V) with 50 µg of SOCS-3 cDNA. Transfected cells were maintained for 20 h in a culture medium containing RPMI 1640, 2 % (v\v) foetal calf serum, 1 % (w\v) glutamine and 1 ng\ml mouse IL-3. Then cells were washed in PBS and cultured for 3 h in X-VIVO culture medium before stimulation.
Reagents
Human recombinant IL-11 (produced in Escherichia coli) was purchased from Roche Diagnostics (Meylan, France). 
Proliferation assays
B13Rα cells were washed twice with PBS, cultured for 3 h in the absence of IL-11 and seeded in 96-well microtitre plates at a density of 20i10$ cells in 50 µl per well. Cells were incubated (in a final volume of 100 µl) with serial dilutions of either human IL-11 (100 ng\ml) or mouse IL-3 (100 ng\ml). Assays were performed in triplicate. After incubation at 37 mC for 72 h, cellular proliferation was assessed by a (4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)-based assay (Sigma Chemical Co.).
Western blot analysis
B13Rα cells were washed twice with PBS and cultured for 3 h in X-VIVO culture medium before stimulation, as indicated. Cells were washed with PBS, and whole-cell or nuclear extracts were prepared as follows. Whole-cell lysates were obtained by lysing cells in buffer containing 50 mM Tris\HCl (pH 7.5), 150 mM NaCl, 0.25 % deoxycholic acid, 1 mM Na $ Vo % , 1 mM NaF, 10 µg\ml aprotinin, 10 µg\ml leupeptin, 1 mM PMSF and 0.1 % Nonidet P40, followed by centrifugation at 12 000 g for 20 min. Nuclear extracts were prepared using the method of Schreiber et al. [29] . Cell extracts were obtained by lysing cells in buffer containing 10 mM Hepes (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol, 0.5 mM PMSF and 0.6 % Nonidet P40. Nuclei were separated from cytosol by centrifugation at 12 000 g for 30 s at 4 mC, resuspended in buffer containing 20 mM Hepes (pH 7.9), 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol and 1 mM PMSF, mixed and incubated at 4 mC for 15 min. Nuclear extracts were obtained by centrifugation at 12 000 g for 5 min at 4 mC. Protein concentration was determined by the bicinchoninic acid (BCA) method (Pierce Chemical Co., Rockford, IL, U.S.A.), with BSA used as a standard. Protein lysates were resolved on an SDS\polyacryl-amide gel, transferred to a PVDF membrane (Millipore, Bedford, MA, U.S.A.) and probed with various antibodies as described. Detection of the antibody-antigen complex was achieved by the enhanced chemiluminescence procedure (ECL kit ; Roche Diagnostics). Blots were used to expose X-Omat Kodak films (Eastman Kodak, Rochester, NY, U.S.A.) for 1 min in order to visualize immunoreactive bands.
Flow cytometric analysis
Cells (1i10&) were cultured for 3 h in X-VIVO culture medium before stimulation with 1 ng\ml IL-3 for 1 h. For gp130 and IL-11Rα staining, mAbs BR-3 and E24.2 respectively were added at a final concentration of 10 µg\ml and incubated on ice for 30 min. After washing (three times), cells were stained with a phycoerythrin-labelled goat anti-mouse antiserum (Immunotech).
RESULTS
Activation of STAT3 by IL-11 and activation of STAT5 by IL-3 in the pro-B cell line B13Rα
Previous results have suggested that IL-3 can suppress the role of IL-11 in the differentiation of primitive B cell progenitors [7, 20] . To study the possible mechanisms by which IL-3 exerts its inhibitory role on IL-11 signalling, we used the mouse pro-B cell line B13Rα, derived from Ba\F3, which can grow in the presence of either IL-3 or IL-11 [28] . We first examined the proliferative response of B13Rα cells. This cell line proliferated in response to either IL-11 or IL-3, with comparable dose responses (Figure 1 ).
Figure 1 Proliferative responses of B13Rα cells stimulated with IL-3 or IL-11
B13Rα cells were seeded in a 96-well plate (20 000 cells/well) and incubated with increasing amounts of IL-3 or IL-11 (as indicated). After 72 h, a tetrazolium compound was added as substrate and the absorbance at 570 nm was measured after a 4 h incubation at 37 mC. Inhibition of interleukin-11-induced activation of STAT3 by interleukin-3
Figure 2 Tyrosine phosphorylation of STAT3 and STAT5 in IL-11-or IL-3-treated B13Rα cells
B13Rα cells were treated for 10 min either with 1 ng/ml IL-3 or 10 ng/ml IL-11. Control cells were left untreated or were preincubated for 15 min with 3 µg/ml BR-3, an anti-(human gp130) mAb which blocks IL-11 signalling, before stimulation with 10 ng/ml IL-11. Whole-cell lysates (50 µg) were loaded on the gel, and immunoblots were performed using antibodies that specifically recognize tyrosine-phosphorylated STAT5 and STAT3 (αSTAT5pY694 and αSTAT3pY705 respectively). Subsequent reblotting with anti-STAT5 and anti-STAT3 was done to verify equal protein loading in each lane.
Half-maximal proliferative responses were obtained at cytokine concentrations compatible with high-affinity interactions, indicating that B13Rα cells express high-affinity receptors for IL-3 and IL-11 on their surface.
We then addressed the specificity of activation of the JAK\ STAT pathway in response to either IL-3 or IL-11. B13Rα cells were stimulated for 10 min with 1 ng\ml IL-3 or 10 ng\ml IL-11. Western blot analysis was performed with antibodies that specifically recognize the phosphotyrosine forms of STAT3 and STAT5. Our results showed that IL-3 strongly induced tyrosine phosphorylation of STAT5, whereas IL-11 promoted tyrosine phosphorylation of STAT3 ( Figure 2 ) and to a lesser extent of STAT1 (results not shown). The effect of IL-11 on the tyrosine phosphorylation of STAT3 was completely inhibited by BR-3, an anti-(human gp130) antibody which blocks the biological effects of all IL-6-type cytokines, including IL-11 [30] (Figure 2 ).
IL-3 suppresses the IL-11-induced tyrosine phosphorylation and nuclear translocation of STAT3
We then examined the potential effects of IL-3 on the IL-11-activated JAK\STAT signalling pathway. B13Rα cells were pretreated with IL-3 for 1 h before the addition of IL-11 for 10 min, and levels of phosphorylated STAT3 were analysed with antibodies that specifically recognize the phosphotyrosine or phosphoserine forms of STAT3. The results indicate that preincubation with IL-3 strongly inhibits the tyrosine phosphorylation of STAT3 induced by IL-11, but does not modify its phosphorylation on serine residues ( Figure 3A) . Since tyrosine phosphorylation of STAT3 is required for its dimerization, translocation to the nucleus and participation in transcriptional regulation via binding to specific DNA sites [31] , we tested the effect of IL-3 on translocation of STAT3 to the nucleus. Nuclear extracts from IL-11-stimulated B13Rα cells pretreated or not with IL-3 were prepared and analysed by Western blot analysis using anti-STAT3 antibodies. Our results showed that the amount of STAT3 is low in the nuclei of cells left untreated or treated with IL-3 before IL-11 stimulation, as compared with the level of STAT3 detected in the nuclei of cells stimulated by IL-11 
Figure 4 Expression of IL-11Rα and gp130 in B13Rα cells
Untreated or IL-3-stimulated cells were labelled with mAb to gp130 (BR-3) or mAb to IL-11Rα (E24.2) and phycoerythrin-conjugated secondary antibody. The control contained secondary antibody alone (shaded area). FL2-H is fluorescence intensity. alone ( Figure 3A) . Furthermore, the active form of STAT3 was only detected in the nuclei of cells treated with IL-11 ( Figure  3B ). These data demonstrate that IL-3 is a potent regulator of the
Figure 5 Inhibitory activity of IL-3 towards STAT3 activation by IL-11 requires new protein synthesis
B13Rα cells were preincubated for 1 h with 1 ng/ml IL-3 alone or a combination of 1 ng/ml IL-3 and 10 µg/ml cycloheximide, and then stimulated for 10 min with 10 ng/ml IL-11. Control cells were either left untreated or stimulated for 10 min with IL-11. Whole-cell lysates were loaded on the gel, and immunoblots were performed using antibodies that specifically recognize tyrosine-phosphorylated STAT3 (αSTAT3pY705). Subsequent reblotting with anti-STAT3 was done to check equal protein loading in each lane. To verify the cycloheximide effect, the membrane was stripped and reblotted using an anti-CIS antibody.
IL-11-activated JAK\STAT signalling pathway, through specific inhibition of the tyrosine phosphorylation of STAT3.
Inhibition of STAT3 activation by IL-3 requires protein synthesis
To investigate further the mechanisms accounting for the decrease in STAT3 activation induced by IL-3, we first tested whether down-regulation of IL-11 receptors might be involved. The levels of expression of IL-11Rα and gp130 were analysed by flow cytometry (Figure 4) ; they were not affected by IL-3 treatment. Next we addressed the question of whether the synthesis of a negative regulator was required for inhibition. Cells were treated with cycloheximide, an inhibitor of protein synthesis, in combination with IL-3 before addition of IL-11. Western blot analysis was performed using an antibody specific for tyrosine-phosphorylated STAT3. We observed that preincubation with cycloheximide resulted in complete reversal of the IL-3-mediated inhibition of STAT3 activation ( Figure 5 ). Full action of cycloheximide was confirmed by full blockade of the synthesis of CIS, a protein that is rapidly induced after stimulation by IL-3 [22] . Altogether, these data demonstrated that the IL-3-mediated inhibitory effect on STAT3 activation by IL-11 was not secondary to a decrease in IL-11 receptors, and required de no o protein synthesis.
Inhibition of STAT3 activation by IL-3 is independent of the ERK and p38 MAP kinase pathways
IL-3 is known to activate multiple signalling pathways in addition to the JAK\STAT pathway [32] , including the three parallel MAP kinase pathways : ERK, c-Jun N-terminal kinase (JNK) and p38 [33, 34] . We first examined the possibility that activation of ERK and p38 might be responsible for the modulation of STAT3 function in B13Rα cells stimulated by IL-3 and IL-11. B13Rα cells were pretreated before stimulation either with PD98059, a highly specific chemical inhibitor of the ERK kinase pathway [35] , or with SB203580, a specific inhibitor of the p38 kinase pathway [36] . Western blot analysis was performed using an antibody specific for tyrosine-phosphorylated STAT3. Neither PD98059 ( Figure 6A ) nor SB203580 ( Figure 6B ) reversed the
Figure 6 Inhibitors of MEK and p38 kinase do not reverse the inhibition of STAT3 activation by IL-3
(A) B13Rα cells were preincubated with 50 µM PD98059 or carrier alone for 1 h before treatment for 1 h with 1 ng/ml IL-3, followed by stimulation for 10 min with 10 ng/ml IL-11. Control cells were either preincubated with carrier alone or stimulated for 10 min with IL-11. (B) B13Rα cells were preincubated with 10 µM SB203580 or carrier for 1 h before treatment for 1 h with 1ng/ml IL-3, followed by stimulation for 10 min with 10 ng/ml IL-11. Control cells were either preincubated with carrier alone or stimulated for 10 min with IL-11. Whole-cell lysates were loaded on the gel, and immunoblots were performed using antibodies that specifically recognize tyrosine-phosphorylated STAT3 (αSTAT3pY705). Subsequent reblotting with anti-STAT3 was done to verify equal protein loading in each lane. (C) B13Rα cells were preincubated with 50 µM PD98059 for 1 h before treatment for 15 min with 1 ng/ml IL-3. Control cells were either preincubated with carrier alone or stimulated for 15 min with 1 ng/ml IL-3. Immunoblots were performed using antibodies that specifically recognize tyrosine-phosphorylated ERK.
negative effect of IL-3 on IL-11-induced STAT3 phosphorylation. These results show that the ERK and p38 kinase pathways are not involved in the inhibition by IL-3 of IL-11-induced STAT3 activation. An inhibitory effect of PD98059 in B13Rα cells stimulated by IL-3 was verified using phospho-ERK antibodies ( Figure 6C ).
Inhibition of STAT3 activation by IL-3 is temporally correlated with expression of SOCS-3
Together, our data strongly suggested that activation of the JAK\STAT signalling pathway by IL-3 was responsible for the down-regulation of IL-11-induced STAT3 activation. Recent results have characterized a novel family of proteins named SOCS\CIS that are induced by various cytokines through the JAK\STAT signalling pathway and are also able, in a feedback regulatory loop, to modulate this pathway [22] [23] [24] [25] [26] . Members of this family might be good candidates as negative regulators of IL-11 signalling in B13Rα cells. We therefore examined whether IL-3 could induce the expression of some of these proteins. The Inhibition of interleukin-11-induced activation of STAT3 by interleukin-3
Figure 7 Induction of SOCS-3 protein is temporally correlated with inhibition of STAT3 activation
(A) Time course of SOCS expression in response to IL-3. B13Rα cells were stimulated with 1 ng/ml IL-3 as indicated. Whole-cell lysates were loaded on the gel, and immunoblots were performed using anti-SOCS-3 and anti-CIS antibodies. (B) Time course of STAT3 inactivation. B13Rα cells were preincubated with 1 ng/ml IL-3 for 5, 20 or 50 min, and then stimulated for 10 min with 10 ng/ml IL-11. Whole-cell lysates were loaded on the gel, and immunoblots were performed using antibodies that specifically recognize tyrosine-phosphorylated STAT3 (αSTAT3pY705).
reverse transcription-PCR experiments indicated that CIS and SOCS-3 mRNAs are highly induced after stimulation by IL-3, while SOCS-1 is moderately induced and SOCS-2 is not induced at all (results not shown). Next, we examined the kinetics of induction of CIS and SOCS-3 proteins, and compared these with a time course of IL-3 pretreatment required for inhibition of IL-11 signalling. Western blotting revealed the strong induction of SOCS-3 protein within 30 min of stimulation by IL-3 ( Figure  7A ). The induced SOCS-3 is maintained for 1 h, decayed within 2 h and was undetectable at 24 h (results not shown). The time course of SOCS-3 expression was correlated with the time course for inhibition of IL-11 signalling ( Figure 7B ). By contrast, the onset of expression of the 32 kDa CIS protein was not temporally linked to STAT3 inhibition (Figure 7) , and the 37 kDa form of CIS (corresponding to ubiquitinated protein [37] ) was detectable after a longer time of exposure. These data demonstrate that CIS is not involved in the inhibitory effect of IL-3 on STAT3 activation and strongly suggest that SOCS-3 is a good candidate to mediate this effect.
SOCS-3 inhibits IL-11-stimulated STAT3 function
To study the effect of SOCS-3 on the termination of IL-11 signalling to STAT3, cDNA encoding an N-terminally Histagged version of SOCS-3 was transiently transfected into B13Rα cells. The treatment of cells with IL-11 for 10 min strongly activated STAT3, as shown by a Western blot of cell extracts probed with an antibody specific for tyrosine-phosphorylated STAT3. STAT3 tyrosine phosphorylation was markedly inhibited in cells expressing SOCS-3 ( Figure 8A ). The expression of SOCS-3 was confirmed by re-probing the Western blot with an antibody to the polyhistidine tag ( Figure 8B ). The apparent
Figure 8 Inhibition by SOCS-3 of IL-11-induced STAT3 tyrosine phosphorylation
(A) B13Rα cells were transiently transfected with a SOCS-3 expression plasmid or empty plasmid. Cells were treated with 10 ng/ml IL-11 for 10 min. Whole-cell lysates were loaded on the gel, and immunoblots were performed using antibodies that specifically recognize tyrosinephosphorylated STAT3 (αSTAT3pY705). Subsequent reblotting with anti-STAT3 was done to verify equal protein loading in each lane. Transfection experiments were repeated twice with the same results. (B) Transfected SOCS-3 protein was visualized using anti-polyhistidine antibody. Molecular masses are indicated on the right. molecular mass of SOCS-3 (" 36 kDa) was in agreement with species of " 32 kDa observed previously (Figure 7 ) fused to a polyhistidine tag. Our results demonstrate that SOCS-3 can inhibit IL-11-induced STAT3 activation.
IL-11 is not able to inhibit IL-3 signalling to STAT5
Since a similar amount of SOCS-3 is also induced by IL-11 ( Figure 9A ), we next examined whether IL-11 can antagonize the
Figure 9 IL-3 signalling to STAT5 is not affected by IL-11
(A) B13Rα cells were treated for 1 h with either 1 ng/ml IL-3 or 10 ng/ml IL-11. Whole-cell lysates were loaded on the gel, and immunoblots were performed using anti-SOCS-3 antibody. (B) B13Rα cells were preincubated for 1 h with 10 ng/ml IL-11 and then treated for 10 min with 1 ng/ml IL-3. Control cells were either left untreated or treated for 10 min with 1 ng/ml IL-3 alone. Whole-cell lysates were loaded on the gel, and immunoblots were performed using a polyclonal antibody to STAT5b that recognizes both phosphorylated STAT5 (upper band ; STAT5-P) and unphosphorylated STAT5. Experiments were performed on two other occasions and gave similar results.
termination of IL-3 signalling to STAT5. B13Rα cells were preincubated with IL-11 for 1 h, then stimulated for 10 min with IL-3. STAT5 activation was monitored by Western blot analysis using an anti-STAT5b antibody that detected unphosphorylated STAT5 and a slower migrating species corresponding to the tyrosine-phosphorylated form. Our results revealed that IL-11 pretreatment did not interfere with IL-3-induced activation of STAT5 ( Figure 9A ).
DISCUSSION
In the present study we investigated the mechanism(s) by which IL-3 suppresses IL-11 signalling in a pro-B cell line, and we demonstrated that antagonistic signals between IL-3 and IL-11 involves cross-talk between JAK\STAT signalling pathways.
Our results show that pretreatment of cells with IL-3 inhibits activation by IL-11 and the nuclear translocation of STAT3. This inhibition is not due to a decrease in IL-11 high-affinity cell surface receptors, and is dependent on de no o protein synthesis. Moreover, the ERK and p38 kinase pathways do not mediate the inhibitory role of IL-3. Furthermore, we showed that IL-3 induces the expression of CIS and SOCS-3, two members of a new family of cytokine-inducible inhibitors of signalling [22, [24] [25] [26] . SOCS-3 production peaks as early as 30 min after stimulation by IL-3, a time which was found to coincide with the onset of STAT3 inactivation. In addition, constitutive expression of SOCS-3, in pro-B cells suppresses IL-11-induced STAT3 activation. Together, these findings strongly suggest that SOCS-3 is, at least in part, involved in the inhibitory process.
SOCS-3 belongs to a family of inhibitor proteins, composed (so far) of eight members, variably called SOCS (suppressors of cytokine signalling) or CIS (cytokine-induced SH2 protein) or SSI (STAT-induced STAT inhibitors) or JAB (JAK binding protein). All these proteins contain an SH2 domain and a Cterminal motif termed the SOCS box or the CIS homology domain. Several of these proteins have been shown to negatively regulate JAK\STAT signalling, but their mechanisms of action appear to be different. CIS, characterized initially as an immediate-early gene, is induced by various cytokines, including IL-2, IL-3, granulocyte-macrophage colony-stimulating factor and erythropoietin [22] , and is STAT5-dependent [38] . CIS can bind to the tyrosine-phosphorylated IL-3 receptor β chain and the erythropoietin receptor [22] and to the IL-2 receptor β chain [39] , but not to gp130, the common transducing chain of the IL-6-type cytokine receptors. Recent studies have shown that CIS is a specific inhibitor of STAT5 in i o [40] . In contrast, SOCS-1 appears to have a larger spectrum of activity, since it inhibits the tyrosine kinase activity of three members of the JAK family [25, 26, 41] . SOCS-1 binds specifically to the tyrosine residue in the activation loop of the kinase domain [42] . Whereas the mechanism of action of SOCS-3 appears to be more complex, the ability of SOCS-3 to inhibit STAT5 activation induced either by IL-2 or by growth hormone requires its binding to activated receptors, as well as to JAK1 [43] or JAK2 [44] . The authors proposed a ' bridge-model ', in which SOCS-3 binds simultaneously to activated growth hormone receptor and JAK2 [44] . SOCS-3 is also known to suppress IL-6-and leukaemia inhibitory factor-dependent STAT3 activation in the M1 leukaemia cell line [45] [46] [47] . Recent studies revealed that the negative effect of SOCS-3 requires the SH2-containing protein tyrosine-phosphatase 2 (SHP2) recruitment site of gp130, reinforcing the SOCS-3 receptor-dependent mechanism of inhibition [48] .
On the basis of our present results and recent findings, we propose the existence of two mechanisms of regulation induced by IL-3 in the mouse pro-B cell line Ba\F3, co-expressing IL-3 and IL-11 receptors. Upon binding of IL-3 to its receptor, the JAK\STAT signalling pathway is activated and rapidly induces the expression of CIS and SOCS-3, with CIS appearing later than SOCS-3. CIS acts as a feedback modulator of IL-3 signalling [23] , whereas SOCS-3 inhibits IL-11 signalling to STAT3. In addition, we show that, despite SOCS-3 protein induction after stimulation by IL-11, inhibition of IL-3 signalling to STAT5 does not occur after preincubation with IL-11 ( Figure 9 ). Our results indicate that SOCS-3 is the first example of a cytokine inhibitor induced by one cytokine, i.e. IL-3, that is not involved in a classical negative feedback loop, but can effectively antagonize a signal delivered by a cytokine belonging to another family, i.e. IL-6-type cytokines. The capacity of SOCS-3 to cross-inhibit cytokine signalling pathways is probably due to its specificity of interaction with particular receptors, such as the IL-2 receptor β chain, the growth hormone receptor or gp130. Since SOCS-1 mRNAs are moderately induced by IL-3, we cannot exclude the possibility that SOCS-1 could also be involved in inhibition of IL-11 signalling.
Previous studies have shown that IL-3 can block the biological activity of IL-6-type cytokines. IL-3 inhibits the anti-apoptotic effect of IL-6 along the differentiation of early plasma cells [21] . Our data suggest that this cross-inhibition might occur through STAT3 inactivation via SOCS-3. This hypothesis is also supported by a study demonstrating that, in the mouse pro-B cell line Ba\F3, the anti-apoptotic signal delivered by IL-6 involves activation of STAT3 [49] . Furthermore, IL-3 totally abrogates the B-cell potential of primary colonies derived from mouse bone marrow obtained after stimulation with a combination of erythropoietin, IL-7 and steel factor plus IL-11, IL-6 or granulocyte colony-stimulating factor [7, 20] . The negative effect of IL-3 might also be due to STAT3 inactivation. Cross-inhibition of cytokine signalling mediated by the transient induction of SOCS-3 provides a novel mechanism by which the interplay between differentiation-and proliferation-inducing signals can be orchestrated during haematopoiesis. Various studies have demonstrated that SOCS-3 is induced not only by growth factors, including IL-2 [43] , IL-3 (the present study), IL-6 [48] , growth hormone [50] , leptin [51] and IL-10 [52] via JAK\STAT pathways, but also by PMA via the ERK\MAP kinase pathway [53] , by tumour necrosis factor-α via the p38\MAP kinase pathway [54] and by lipopolysaccharide [55] , suggesting a critical role for SOCS-3 in cross-regulation between these mediators and the JAK\STAT pathway induced by IL-6 [53] , IL-11 (the present study) or interferon-α and -γ [52] . These findings strongly support a crucial role for SOCS-3 in the negative cross-talk between a large number of mediators and cytokines.
